AbbVie (ABBV) Return on Capital Employed (2013 - 2026)

AbbVie has disclosed Return on Capital Employed across 14 years of filings, most recently posting 16.47% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 632.0% year-over-year to 16.47%; the TTM figure through Mar 2026 stood at 16.47% (up 632.0% YoY), while the FY2025 annual figure was 16.52%, up 702.0% from the prior year.
• Return on Capital Employed eased to 16.47% in Q1 2026, from 16.63% in the prior quarter.
• Over the last five years, Return on Capital Employed for ABBV reached as high as 16.93% in Q2 2023 and fell as low as 9.09% in Q4 2024.
• The 5-year median for Return on Capital Employed is 14.82% (2023), against an average of 13.9%.
• Annual changes were most pronounced in 2024 — Return on Capital Employed sank 507 bps — and 2025, when it jumped 754 bps.
• A 5-year view of Return on Capital Employed shows it stood at 16.39% in 2022, then dropped by 20 bps to 13.07% in 2023, then sank by 30 bps to 9.09% in 2024, then jumped by 83 bps to 16.63% in 2025, then declined by 1 bps to 16.47% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 16.47%, 16.63%, and 9.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.